WLWei Li

Wei Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wei Li has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • Wenjie Zhang

    Department of Plastic and Reconstructive Surgery, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Tissue Engineering, National Tissue Engineering Center of China, No. 639 Zhi-zao-ju Road, Shanghai, 200011, China

    17 shared publications
  • Yizuo Cai

    Department of Plastic and Reconstructive Surgery , Shanghai Ninth People’s Hospital , Shanghai Jiao Tong University School of Medicine , Shanghai , China , shsmu.edu.cn

    16 shared publications
  • Bijun Kang

    Department of Plastic and Reconstructive Surgery, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Tissue Engineering National Tissue Engineering Center of China Shanghai China

    9 shared publications
  • Zhuoxuan Jia

    Department of Plastic and Reconstructive Surgery , Shanghai Ninth People’s Hospital , Shanghai Jiao Tong University School of Medicine , Shanghai , China , shsmu.edu.cn

    9 shared publications
  • Qian Yu

    Department of Plastic and Reconstructive Surgery , Shanghai Ninth People’s Hospital , Shanghai Jiao Tong University School of Medicine , Shanghai , China , shsmu.edu.cn

    7 shared publications
  • Xiangsheng Wang

    Department of Plastic and Reconstructive Surgery, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Tissue Engineering, National Tissue Engineering Center of China, Shanghai, China

    7 shared publications

Latest Publications

  • Open Access

    Improvement of Periorbital Wrinkles With 1565‐nm Fractional Er:Glass Laser in Asian Patients

    by Hongjie Zheng, Zhuoxuan Jia, Bijun Kang, Yizuo Cai, Qian Yu, Yichen Zhang, Wenjie Zhang, Wei Li

    Background: Periorbital wrinkles are among the earliest signs of facial aging. Objective: This study evaluates the efficacy, safety, and associated histological changes of 1565‐nm Er:glass nonablative fractional laser (NAFL) for periorbital wrinkle reduction. Methods: In this assessor‐blinded, prospective, split‐face randomized study, 20 Asian patients received 5 sessions of 1565‐nm NAFL on one periorbital side at 4‐week intervals. Wrinkle severity was assessed via the Fitzpatrick Wrinkle Classification System (FWCS), standardized photograph‐based wrinkle length measurements, and wrinkle reduction rate. Transepidermal water loss (TEWL), pain visual analog scale (VAS), patient satisfaction (LSS), and adverse events were recorded. A parallel animal study ( n = 9) was performed to evaluate histological changes after treatment. Results: In the clinical study, the treated side showed significant improvement in periorbital wrinkles, with the FWCS score decreased from 3.23 ± 1.10 at baseline to 2.09 ± 1.00 at 3 months after treatment ( p < 0.001). Standardized photograph‐based assessment showed a mean wrinkle length reduction of 14.60% on the treated side. No severe adverse events were reported, and TEWL remained stable from baseline to the 3‐month follow‐up. The animal study showed increased epidermal and dermal thickness and collagen deposition in treated skin. Conclusion: The 1565‐nm Er:glass NAFL may be an effective and safe treatment for improving mild‐to‐moderate periorbital wrinkles in young Asian adults, with supportive histological evidence of epidermal and dermal remodeling.

  • Open Access

    Recombinant Human Annexin A5 Ameliorates Localized Scleroderma by Inhibiting the Activation of Fibroblasts and Macrophages

    by Bijun Kang, Zhuoxuan Jia, Wei Li, Wenjie Zhang

    Background: Localized scleroderma (LoS) is a chronic autoimmune condition marked by cutaneous fibrosis and persistent inflammation. Modulating the activation of inflammatory cells and fibroblasts remains a central strategy in LoS treatment. We investigate the anti-fibrotic effects of Annexin A5 (AnxA5), identified as a key inflammatory component in fat extract, and assess its therapeutic efficacy. Methods: In vitro experiments were performed using TGF-β-stimulated primary human dermal fibroblasts treated with recombinant AnxA5. The anti-fibrotic effects and underlying mechanisms were assessed using CCK-8 assays, quantitative real-time PCR, Western blotting, and immunocytochemistry. In vivo, AnxA5 was administered via both preventative and therapeutic protocols in bleomycin-induced LoS mouse models. Treatment outcomes were evaluated by histological staining, collagen quantification, immunostaining, and measurement of pro-inflammatory cytokines. Results: TGF-β stimulation induced myofibroblast differentiation and extracellular matrix (ECM) production in dermal fibroblasts, both of which were significantly attenuated by AnxA5 treatment through the inhibition of phosphorylation of Smad2. In vivo, both preventative and therapeutic administration of AnxA5 effectively reduced dermal thickness, collagen deposition, ECM accumulation, M1 macrophage infiltration, and levels of pro-inflammatory cytokines. Conclusions: Through both preventative and therapeutic administration, AnxA5 ameliorates LoS by exerting dual anti-fibrotic and anti-inflammatory effects, underscoring its potential for treating fibrotic diseases.


  • Open Access

    Autologous Cell‐Free Fat Extract: A Novel Approach for Infraorbital Rejuvenation—A Pilot Study

    by Yizuo Cai, Zhuoxuan Jia, Jiancheng Gu, Bijun Kang, Wei Li, Wenjie Zhang

    Background and Objective: CEFFE (Cell‐free fat extract) treatment for periocular fine lines requires thorough clinical evaluation to determine its efficacy and safety in enhancing skin quality. The research enrolled 10 healthy female participants aged 31–58, focusing on skin texture, elasticity, and barrier function. Methods and Results: CEFFE treatment demonstrated significant benefits, with notable improvements observed as early as 3 months posttreatment, which continued throughout the 12‐month follow‐up period. Objective assessments revealed reductions in SEr% and SEw%, indicative of reduced skin roughness and wrinkles, particularly pronounced after the third month of treatment. Enhanced skin elasticity, as indicated by improvements in R2%, R5%, and R7%, was observed, with the most significant enhancements noted at the 6‐month follow‐up. Furthermore, TEWL decreased consistently, highlighting CEFFE's potential in maintaining the skin's barrier function and moisture retention. High patient satisfaction levels, with 70% expressing satisfaction ranging from satisfied to very satisfied, underscored CEFFE's clinical significance. Conclusions: CEFFE demonstrates potential as an effective and safe intervention for addressing periocular fine lines, providing a solution for fine lines while ensuring skin health (ChiCTR1900024329).


  • Cell-Free Fat Extract with Anti-melanogenic Property Improves the Appearance of Infraorbital Dark Circles: A Preliminary Clinical Study

    by Bijun Kang, Yizuo Cai, Zhuoxuan Jia, Liudi Yao, Jiancheng Gu, Wei Li, Wenjie Zhang

    Background The formation of infraorbital dark circles involves various factors including hyperpigmentation, skin aging and laxity. This study is to investigate whether cell-free fat extract (CEFFE) inhibits melanin synthesis and improves the appearance of infraorbital dark circles. Methods Imaging systems analysed the melanin content in three groups of zebrafish embryos treated with 0 (CTRL), 100, and 200μg/mL of CEFFE. Eleven patients with infraorbital dark circles were enrolled and received intradermal injections of autologous CEFFE. Clinical trial assessments included subjective assessments (Global Aesthetic Improvement Scale and Likert satisfaction scale) and objective assessments (standard two-dimensional photographs, VISIA® photographs, and infraorbital skin colour measurement). Results In the experiment of zebrafish embryos, the melanin content of CEFFE treatment was significantly reduced. In clinical trial, 72.73% of patients considered CEFFE treatment for infraorbital dark circles to be effective, and more than half of the patients were satisfied with the treatment. In the evaluation of skin colour at the inner, middle, and outer edges of the infraorbital dark circles, there was a gradual improvement in infraorbital skin colour after each treatment and at the 3-month follow-up, with a statistically significant improvement in skin colour on the outer edge of the infraorbital dark circles (p < 0.05). Simultaneously, we observed a reduction in periocular wrinkles, with a significant difference at the 3-month follow-up (p < 0.05). The events observed included bruising, erythema, and oedema, which resolved spontaneously. Conclusion Our study demonstrated that CEFFE inhibits melanogenesis and is a safe and effective treatment for infraorbital dark circles. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.


  • Open Access

    Recombinant human annexin A5 accelerates diabetic wounds healing by regulating skin inflammation

    by Bijun Kang, Zhuoxuan Jia, Yushan Dong, Wei Li, Wenjie Zhang


  • Open Access

    Annexin A5 Derived from Cell-free Fat Extract Attenuates Osteoarthritis via Macrophage Regulation

    by Zhuoxuan Jia, Bijun Kang, Yushan Dong, Mingzhe Fan, Wei Li, Wenjie Zhang

    Osteoarthritis (OA) is a challenging degenerative joint disease to manage. Previous research has indicated that cell-free fat extract (CEFFE) may hold potential for OA treatment. This study investigated the role of Annexin A5 (AnxA5) within CEFFE in regulating macrophage polarization and protecting chondrocytes. In vitro experiments demonstrated that AnxA5 effectively inhibited M1 macrophage polarization by facilitating toll-like receptor (TLR) 4 internalization and lysosomal degradation through calcium-dependent endocytosis. This process decreased TLR4 expression, suppressed pro-inflammatory mediator release, and reduced the production of reactive oxygen species. Furthermore, AnxA5 displayed protective effects against chondrocyte necrosis and apoptosis. In vivo, studies revealed that intra-articular administration of AnxA5 ameliorated pain symptoms in a monosodium iodoacetate-induced osteoarthritis rat model. Histological analyses indicated a decrease in synovial inflammation and mitigation of cartilage damage following AnxA5 treatment. These results underscored the potential of AnxA5 as a therapeutic option for OA due to its capacity to regulate macrophage polarization and maintain chondrocyte viability. Further investigation into the specific mechanisms and clinical applications of AnxA5 may help improve the management of OA.


  • Carbon Footprint Tracking Based on Non-intrusive Load Monitoring Technology

    by Bin Xiao, Wei Zhang, Min Liu, Yong Qi, Wei Li

    With the growing concern for environmental sustainability and the need to mitigate climate change, accurately tracking carbon footprints has become crucial. This paper explores the use of NILM technology for carbon footprint tracking at the household level. A carbon footprint tracking model is proposed based on NILM technology. On this basis, the relationship between carbon footprint and NILM technology is explored. An example is designed to verify the validity of NILM technology in calculating carbon footprint. The simulation results show that the NILM technology can be used to track the carbon footprint at the household. Finally, the paper is summarized.


  • Open Access

    Cell-free fat extract restores hair loss: a novel therapeutic strategy for androgenetic alopecia

    by Yizuo Cai, Zhuoxuan Jia, Yichen Zhang, Bijun Kang, Chingyu Chen, Wei Liu, Wei Li, Wenjie Zhang

    Background: Androgenetic alopecia (AGA) is one of the most common hair loss diseases worldwide. However, current treatments including medicine, surgery, and stem cells are limited for various reasons. Cell-free fat extract (CEFFE), contains various cell factors, may have potential abilities in treating AGA. This study aims to evaluate the safety, effectiveness and the underlying mechanism of CEFFE in treating AGA.Methods: Sex hormone evaluation, immunogenicity assay and genotoxicity assay were conducted for CEFFE. In vivo study, male C57BL/6 mice were injected subcutaneously with dihydrotestosterone (DHT) and were treated with different concentration of CEFFE for 18 days (five groups andn = 12 in each group: Control, Model, CEFFELow, CEFFEMiddle, CEFFEHigh). Anagen entry rate and hair coverage percentage were analyzed through continuously taken gross photographs. The angiogenesis and proliferation of hair follicle cells were evaluated by hematoxylin–eosin, anti-CD31, and anti-Ki67 staining. In vitro study, dermal papilla cells (DPCs) were incubated with different concentrations of CEFFE, DHT, or CEFFE + DHT, followed by CCK-8 assay and flow cytometry to evaluate cell proliferation cycle and apoptosis. The intracellular DHT level were assessed by enzyme-linked immunosorbent assay. The expression of 5α-reductase type II, 3α-hydroxysteroid dehydrogenase and androgen receptor were assessed through reverse transcription-quantitative polymerase chain reaction (RT-qPCR) or/and western blot.Results: In CEFFE-treated mice, an increase in the anagen entry rate and hair coverage percentage was observed. The number of CD31-positive capillaries and Ki67-positive cells were increased, suggesting that CEFFE promoted the proliferation of DPCs, modulated the cell cycle arrest, inhibited apoptosis caused by DHT, reduced the intracellular concentration of DHT in DPCs, and downregulated the expression of AR.Conclusions: CEFFE is a novel and effective treatment option for AGA through producing an increased hair follicle density and hair growth rate. The proposed mechanisms are through the DHT/AR pathway regulation and regional angiogenesis ability.


  • Open Access

    Intradermal Local Injection of Autologous Cell‐Free Fat Extract for the Treatment of Refractory Postinflammatory Hyperpigmentation

    by Yizuo Cai, Zhuoxuan Jia, Jiancheng Gu, Bijun Kang, Hongjie Zheng, Wei Li, Wenjie Zhang

    Current treatment modalities for postinflammatory hyperpigmentation (PIH) often fall short in delivering satisfactory results for some patients. Therefore, this study aimed to assess the efficacy and tolerability of autologous cell‐free fat extract (CEFFE) in the treatment of PIH. We enrolled 15 patients with PIH and administered them with five intracutaneous CEFFE injections, each at a two‐week interval. Evaluation included efficacy assessment using objective (standard two‐dimensional photos, VISIA®‐photos, brown spot (BS) index, lesion lightness, lesion color, and trans‐epidermal water loss) and subjective (Global Aesthetic Improvement Scale and Likert satisfaction scale) parameters and tolerance assessment. Following CEFFE treatment, significant reductions were observed in the BS index (p < 0.05) and transepidermal water loss (p < 0.05), while skin lightness and lesion color showed significant improvements (p < 0.05) at the 12‐month follow‐up. Subjectively, 93.33% of patients reported improved or greatly improved conditions after 12 months of treatment. Transient local bruising and stinging were the only observed treatment‐related adverse events, with no serious complications reported. These findings demonstrate that intradermal injections of CEFFE are well‐tolerated and effective for the treatment of PIH. This trial is registered with ChiCTR2000039381.


  • Predictors of treatment responses of superficial infantile hemangiomas to topical timolol

    by Hongjie Zheng, Yizuo Cai, Yuda Xu, Qian Yu, Bijun Kang, Chingyu Chen, Xia Gong, Wei Li

    Topical timolol is not effective in the treatment of some superficial infantile hemangiomas (IHs). This is a prospective study aiming to investigate the predictors of treatment response of superficial IHs to topical timolol. Patients with superficial IHs were prescribed timolol 0.5% cream four times daily and followed up every 2-3 months until 1 year of age. IH thickness was objectively measured by ultrasound, and the proportional change was calculated as a regression rate. In total, 193 patients (211 lesions) were enrolled. Topical timolol was initiated at an average age of 3.1 (0-6) months for 7.4 (2-11) months. The average regression rate of all lesions was 41.8% (-137.5%-100%). Lesion thickness (p = 0.000) and patient age at initial treatment (p = 0.001) were major variables that predicted the treatment response. On average, an increase in lesion thickness of 1 mm decreased the regression rate by 22.1%, and lesions thicker than 1.9 mm were unlikely to respond (average regression rate = -0.27%). Available results did not show a significant effect of sex (p = 0.659), lesion size (p = 0.311), or location (p > 0.05) on regression. Treatment for superficial IHs should be individualized according to lesion thickness and patient age.